Lifecore Biomedical Statistics
Want to see LFCR full AI Analyst Report?
Lifecore Biomedical (LFCR) Stock Statistics & Valuation Metrics
Total Valuation
Lifecore Biomedical has a market cap or net worth of $243.36M. The enterprise value is $439.30M.
- Market Cap
- $243.36M
- Enterprise Value
- $439.30M
Share Statistics
Lifecore Biomedical has 37,905,846 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 37,905,846
- Owned by Insiders
- 15.99%
- Owned by Institutions
- 30.14%
Financial Efficiency
Lifecore Biomedical’s return on equity (ROE) is 2.17 and return on invested capital (ROIC) is -0.60%.
- Return on Equity (ROE)
- 2.17
- Return on Assets (ROA)
- -0.13
- Return on Invested Capital (ROIC)
- -0.60%
- Return on Capital Employed (ROCE)
- -0.01
- Revenue Per Employee
- 338.91K
- Profits Per Employee
- -80.60K
- Employee Count
- 382
- Asset Turnover
- 0.56
- Inventory Turnover
- 3.06
Valuation Ratios
The current PE Ratio of Lifecore Biomedical is -3.40. Lifecore Biomedical’s PEG ratio is 0.04.
- PE Ratio
- -3.40
- PS Ratio
- 2.08
- PB Ratio
- -3.31
- Price to FCF
- 47.79
- Price to Operating Cash Flow
- 24.85
- PEG Ratio
- 0.04
Income Statement
In the last 12 months, Lifecore Biomedical had revenue of 129.46M and earned -30.79M in profits. Earnings per share was -0.92.
- Revenue
- 129.46M
- Gross Profit
- 40.61M
- Operating Income
- -1.26M
- Pretax Income
- -30.21M
- Net Income
- -30.79M
- EBITDA
- 5.98M
- Earnings Per Share (EPS)
- -0.92
Cash Flow
In the last 12 months, operating cash flow was 3.05M and capital expenditures -3.15M, giving a free cash flow of -106.28K billion.
- Operating Cash Flow
- 3.05M
- Free Cash Flow
- -106.28K
- Free Cash Flow per Share
- 0.13
Dividends & Yields
Lifecore Biomedical pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- 2.09%
- Earnings Yield
- -27.73%
Stock Price Statistics
- Beta
- 1.77
- 52-Week Price Change
- -18.63%
- 50-Day Moving Average
- 5.79
- 200-Day Moving Average
- 5.34
- Relative Strength Index (RSI)
- 63.79
- Average Volume (3m)
- 403.05K
Important Dates
Lifecore Biomedical upcoming earnings date is May 12, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Nov 04, 2026
- Next Earnings Date
- May 12, 2027
- Ex-Dividend Date
- ―
Financial Position
Lifecore Biomedical as a current ratio of 3.49, with Debt / Equity ratio of -1004.14%
- Current Ratio
- 3.49
- Quick Ratio
- 2.26
- Debt to Market Cap
- 0.45
- Net Debt to EBITDA
- 20.91
- Interest Coverage Ratio
- -0.05
Taxes
In the past 12 months, Lifecore Biomedical has paid 577.71K in taxes.
- Income Tax
- 577.71K
- Effective Tax Rate
- -0.02
Enterprise Valuation
Lifecore Biomedical EV to EBITDA ratio is -15.32, with an EV/FCF ratio of 87.09.
- EV to Sales
- 3.80
- EV to EBITDA
- -15.32
- EV to Free Cash Flow
- 87.09
- EV to Operating Cash Flow
- 45.35
Balance Sheet
Lifecore Biomedical has $17.47M in cash and marketable securities with $142.61M in debt, giving a net cash position of -$125.14M billion.
- Cash & Marketable Securities
- $17.47M
- Total Debt
- $142.61M
- Net Cash
- -$125.14M
- Net Cash Per Share
- -$3.30
- Tangible Book Value Per Share
- -$1.28
Margins
Gross margin is 30.33%, with operating margin of -0.37%, and net profit margin of -57.66%.
- Gross Margin
- 30.33%
- Operating Margin
- -0.37%
- Pretax Margin
- -57.54%
- Net Profit Margin
- -57.66%
- EBITDA Margin
- -24.77%
- EBIT Margin
- -31.05%
Analyst Forecast
The average price target for Lifecore Biomedical is $6.28, which is 11.43% higher than the current price. The consensus rating is Neutral
- Price Target
- $6.28
- Price Target Upside
- 2.18% Downside
- Analyst Consensus
- Neutral
- Analyst Count
- 3
- Revenue Growth Forecast
- ―
- EPS Growth Forecast
- ―
Scores
- Smart Score
- 4
- AI Score
- 52

